Global Cancer ALK Inhibitor Market is estimated to be US$ 10.6 billion by 2030 with a CAGR of 22.0% during the forecast period - by PMI

 | Source: PMI PMI

Covina, CA, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to register a CAGR of 22.0%. ALK inhibitors are anti-cancer drugs that acts on tumors with variations of anaplastic lymphoma kinase such as EML4-ALK translocation and falls in the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in abnormal growth of tumor cells. All the ALK inhibitors present today in the market function by binding to ATP pocket of abnormal ALK protein, blocking its access to energy and deactivating it.

The report "Global Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Request a Free Sample Copy of this Business Intelligence Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4665

Key Highlights:

  • Global Phase III clinical trial (eXalt3) is going on comparing Ensartinib to Crizotinib in TKI nave ALK positive patient. Primary purpose for this study is to evaluate the efficacy and safety of ensartinib vs. crizotinib in patients with ALK-positive.
  • Xcovery is investigating drug candidate, Ensartinib which is best-in-class oral compound for first-line treatment of ALK-positive NSCLC.

Analyst View:

Increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market. Many key players are coming with new drugs and new technologies. Various organizations such as W.H.O., FEAT, and others along with the government are spreading awareness about this syndrome condition which is anticipated to facilitate market growth in the forecast period.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-Cancer-ALK-Inhibitor-Market-4665

Key Market Insights from the report:

The Global Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to register a CAGR of 22.0%. The Global Cancer ALK Inhibitor Market is segmented based on the Drug, Type, Distribution Channel and region.

  • By Drug, the Global Cancer ALK Inhibitor Market is segmented into Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena).
  • By Type, the market is segmented in First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors.
  • By Distribution Channel, the Global Cancer ALK Inhibitor Market is segmented into Hospital pharmacies, Online Pharmacies and Others.
  • By region, the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Ask for a Discount on the Current Pricing @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/4665

Competitive Landscape:

The key players operating in the Global Cancer ALK Inhibitor Market include AstraZeneca Plc

Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc..

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

  • Explains an overview of the product portfolio, including product development, planning, and positioning
  • Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
  • Detailed analysis of the market revenue over the forecasted period.
  • Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
  • Study on the segments that are anticipated to dominate the market.
  • Study on the regional analysis that is expected to register the highest growth over the forecast period

Key Topics Covered

  1. Introduction
  • Study Deliverables
  • Study Assumptions
  • Scope of the Study
  1. Research Methodology
  2. Executive Summary
  • Opportunity Map Analysis
  • Market at Glance
  • Market Share (%) and BPS Analysis, by Region
  • Competitive Landscape
  • Heat Map Analysis 
  • Market Presence and Specificity Analysis
  1. Investment Analysis
  2. Competitive Analysis

Browse Related Reports:

  1. https://www.prophecymarketinsights.com/PressRelease/Global-MEK-inhibitor-Market-1162
  2. https://www.prophecymarketinsights.com/PressRelease/Global-PD1-&-PDL1-Inhibitor-Market-1163
  3. https://www.prophecymarketinsights.com/PressRelease/Global-PARP-Inhibitor-Market-1164
 

            








        

            

                

                    
Tags

                            
                                Cancer ALK Inhibitor Market
                            
                            
                                AstraZeneca
                            
                            
                                Betta Pharmaceuticals
                            
                            
                                Bio-Techne Corp.
                            
                            
                                GlaxoSmithKline
                            

                



        




    

        

        
Contact Data